home / stock / trov / trov quote
Last: | $1.19 |
---|---|
Change Percent: | -0.83% |
Open: | $1.19 |
Close: | $1.19 |
High: | $1.19 |
Low: | $1.16 |
Volume: | 166,427 |
Last Trade Date Time: | 05/07/2020 04:47:16 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.19 | $1.19 | $1.19 | $1.19 | $1.16 | 166,427 | 05-07-2020 |
$1.2 | $1.29 | $1.2 | $1.29 | $1.16 | 289,548 | 05-06-2020 |
$1.2568 | $1.22 | $1.2568 | $1.28 | $1.21 | 233,755 | 05-05-2020 |
$1.215 | $1.17 | $1.215 | $1.25 | $1.12 | 275,611 | 05-04-2020 |
$1.1501 | $1.23 | $1.1501 | $1.24 | $1.13 | 264,157 | 05-01-2020 |
$1.24 | $1.25 | $1.24 | $1.26 | $1.18 | 396,330 | 04-30-2020 |
$1.1 | $1.12 | $1.1 | $1.124 | $1.01 | 355,913 | 04-29-2020 |
$1.11 | $1.4277 | $1.11 | $1.67 | $1.09 | 12,713,837 | 04-28-2020 |
$1.07 | $0.965 | $1.07 | $1.115 | $0.9625 | 676,980 | 04-27-2020 |
$0.9653 | $0.947 | $0.9653 | $0.97 | $0.92 | 151,968 | 04-24-2020 |
$0.9499 | $0.92 | $0.9499 | $0.965 | $0.9013 | 137,086 | 04-23-2020 |
$0.93 | $0.88 | $0.93 | $0.9454 | $0.86 | 257,258 | 04-22-2020 |
$0.9 | $0.93 | $0.9 | $0.93 | $0.85 | 156,941 | 04-21-2020 |
$0.9 | $0.97 | $0.9 | $0.97 | $0.9 | 168,801 | 04-20-2020 |
$0.932 | $0.9975 | $0.932 | $1.02 | $0.92 | 205,230 | 04-17-2020 |
$0.9605 | $0.9403 | $0.9605 | $1.0451 | $0.93 | 62,326 | 04-16-2020 |
$0.9787 | $1.03 | $0.9787 | $1.03 | $0.9 | 126,376 | 04-15-2020 |
$1.0201 | $1 | $1.0201 | $1.1 | $1 | 250,207 | 04-14-2020 |
$0.96 | $0.95 | $0.96 | $1 | $0.9002 | 220,590 | 04-13-2020 |
$0.91 | $0.79 | $0.91 | $0.9226 | $0.79 | 224,342 | 04-10-2020 |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...